Wireframe preview

Best viewed on desktop.

This is a wireframe for review, not the finished site. The responsive (mobile) treatment comes in the design and build phase. Open this page on a screen at least 1200 px wide to see the layout as intended.

← The GRA Portfolio

Cyanvac

Vaccines

Cyanvac develops vaccines using parainfluenza virus 5 (PIV5) as a vector. The company is currently focused on developing robust, intranasal vaccines that are easy to administer, easy to transport and easy to manufacture.

Two of Cyanvac’s vaccine candidates are scheduled to enter clinical testing beginning in 2021, including an intrasal vaccine to serve as a booster for protecting against SARS-CoV-2 infection. The candidate was selected for the trail by an academic consortium that has run government-funded trials for other COVID-19 vaccines, and the clinical evaluation will be conducted at no cost to Cyanvac.

Cyanvac also has vaccine candidates for respiratory syncytial virus (RSV), norovirus and Lyme Disease.